focus -WSS

focus

author：explore 2025-10-02 18:47:19 - browse：924

Geoff Martha, CEO of Medtronic Courtesy Medtronic

As one of the largest and oldest medical device companies in the world, Medtronic has a foot in almost every clinical area.

The device maker with a market valuation of nearly $100 billion sells pacemakers, spinal cord stimulators, stents, monitors. Name a device, and they probably make it. The behemoth is ubiquitous in health care, but its size can make innovation sluggish. Medtronic has tried to become more streamlined in recent years — the company announced plans last year to spin off its patient monitoring and respiratory businesses, which Reuters recently reported, citing unnamed sources, may go to the Carlyle Group, a private equity firm.

Still, the device giant is immersed in many different specialties, including diabetes and high blood pressure, where the company has experienced some setbacks. Medtronic has sold old-school insulin pumps since the 1980s and therefore developed robust dosing algorithms, but has never successfully built a tubeless pump. The company plans to buy Korean patch pump maker EOFlow, but EOFlow is enmeshed in a patent battle with Insulet. A federal judge blocked EOFlow from selling its wearable patch pumps earlier this month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Readout LOUD podcast: How biotech is using artificial intelligence

WSS

Medical mystery: When a cough is not just a cough

Anthony Fauci pushes back on GOP claims during Covid hearing

Finland to offer bird flu vaccine to select groups of people, a possible global first

Structure Therapeutics oral GLP

Biden report: The neurospychology of memory and aging

The Readout: Gilead, Bernie Sanders, and other pharma news

hotspot

focus

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Medicare details structure of new drug price negotiation program

Elevance PBM president out as customers face prescription chaos

Affirmative action in medical school literally saved lives

Elevance PBM president out as customers face prescription chaos

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Data don't support strong claims for Covid

Medical records are filled with copy

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

focus

FDA approves Moderna’s RSV vaccine, its second licensed product

UnitedHealth CEO's Medicaid comments send insurer stocks diving

To avoid data mishandling cases, universities eye AI and other tools

'Revelatory' study finds a smoking impact that remains after quitting

Robert F. Kennedy is pitching centrism on health, even on abortion

A disappointing year of Humira biosimilars

focus

hotspot

Wikipedia

entertainment